hims stock revenue guidance august earnings

**Hims & Hers Health's stock revenue guidance and August earnings reveal a company on an upward trajectory**, with strong growth metrics and strategic targets despite recent legal challenges.

1. **Financial Performance and Guidance**:
- Hims & Hers Health reported a robust Q1 2025 with revenue doubling year-over-year to $586 million, surpassing analyst estimates by 8.3%.
- The company added 137,000 customers, bringing the total to 2.37 million, reflecting significant market expansion.
- For Q2 2025, analysts anticipate a 74.5% year-on-year revenue growth to $550.8 million.
- Full-year 2025 revenue guidance is $2.3 billion to $2.4 billion, with adjusted EBITDA guidance ranging from $295 million to $335 million.
- Hims & Hers has set ambitious long-term targets, projecting at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030.
2. **Market Reaction and Analyst Sentiment**:
- Despite strong financials, the company's stock fell post-earnings due to missed revenue projections for Q2.
- Analysts maintain an average price target of $48.36, suggesting potential upside from the current share price of $62.48.
- The stock's recent decline presents a buying opportunity, according to the company's positive long-term outlook.
3. **Legal Challenges and Impact**:
- Hims & Hers faces a securities class action lawsuit over allegations of deceptive promotion and patient safety risks related to its partnership with Novo Nordisk.
- The legal issues have caused stock volatility, with a significant drop in June 2025 following Novo Nordisk's partnership termination.
- Investor attention is divided between the company's growth prospects and the legal risks it faces.
4. **Strategic Positioning and Growth Focus**:
- Hims & Hers emphasizes ecosystem collaboration, aiming to strengthen its platform through partnerships with pharmaceutical leaders and diagnostic innovators.
- The company's focus on consumer-driven healthcare and precision medicine positions it to capture a broader market.

In conclusion, while Hims & Hers Health faces short-term legal challenges, its strong financial performance, strategic growth initiatives, and ambitious long-term targets indicate a promising outlook. Investors should weigh the potential for long-term growth against the immediate risks posed by the legal issues.